> Details

Saußele, Susanne [Author]; Krauß, Marie-Paloma [Author]; Hehlmann, Rüdiger [Author]; Proetel, Ulrike [Author]; Kalmanti, Lida [Author]; Hanfstein, Benjamin [Author]; Fabarius, Alice [Author]; Hofmann, Wolf-Karsten [Author]; Müller, Martin Christian [Author]

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia : results of the randomized CML Study IV

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Impact of comorbidities on overall survival in patients with chronic myeloid leukemia : results of the randomized CML Study IV
  • Contributor: Saußele, Susanne [VerfasserIn]; Krauß, Marie-Paloma [VerfasserIn]; Hehlmann, Rüdiger [VerfasserIn]; Proetel, Ulrike [VerfasserIn]; Kalmanti, Lida [VerfasserIn]; Hanfstein, Benjamin [VerfasserIn]; Fabarius, Alice [VerfasserIn]; Hofmann, Wolf-Karsten [VerfasserIn]; Müller, Martin Christian [VerfasserIn]
  • imprint: 2 July 2015
  • Published in: Blood ; 126(2015), 1, Seite 42-49
  • Language: English
  • DOI: 10.1182/blood-2015-01-617993
  • ISSN: 1528-0020
  • Identifier:
  • Origination:
  • Footnote:
  • Description: We studied the influence of comorbidities on remission rate and overall survival (OS) in patients with chronic myeloid leukemia (CML). Participants of the CML Study IV, a randomized 5-arm trial designed to optimize imatinib therapy, were analyzed for comorbidities at diagnosis using the Charlson Comorbidity Index (CCI); 511 indexed comorbidities were reported in 1519 CML patients. Age was an additional risk factor in 863 patients. Resulting CCI scores were as follows: CCI 2, n = 589; CCI 3 or 4, n = 599; CCI 5 or 6, n = 229; and CCI ≥ 7, n = 102. No differences in cumulative incidences of accelerated phase, blast crisis, or remission rates were observed between patients in the different CCI groups. Higher CCI was significantly associated with lower OS probabilities. The 8-year OS probabilities were 93.6%, 89.4%, 77.6%, and 46.4% for patients with CCI 2, 3 to 4, 5 to 6, and ≥7, respectively. In multivariate analysis, CCI was the most powerful predictor of OS, which was still valid after removal of its age-related components. Comorbidities have no impact on treatment success but do have a negative effect on OS, indicating that survival of patients with CML is determined more by comorbidities than by CML itself. OS may therefore be inappropriate as an outcome measure for specific CML treatments. The trial was registered at www.clinicaltrials.gov as #NCT00055874.
  • Access State: Open Access